<DOC>
	<DOCNO>NCT00631579</DOCNO>
	<brief_summary>The primary objective study evaluate safety efficacy patient malignant lymphoma acute leukemia repeatedly administer SR29142 5 day two dosage group . Secondary objective determine pharmacokinetic ( PK ) parameter SR29142 , assess anti-SR29142 antibody production patient malignant lymphoma acute leukemia , estimate optimal dosage SR29142 Japanese patient result efficacy safety evaluation .</brief_summary>
	<brief_title>Rasburicase Uricolytic Therapy Hyperuricemia Patients With Leukemia Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>Patient suffering : acute leukemia white blood cell ( WBC ) count≥ 20,000/mm3 without regard uric acid level ; lymphoma , Stage ≥ III without regard uric acid level ; lymphoma , Stage II bulky disease ; lymphoma leukemia , without regard classification morphology , uric acid level ≥ 8.0 mg/dL , lactate dehydrogenase ( LDH ) level ≥ twice upper limit normal ( ULN ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>